Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer-Reference-Cited by-同舟云学术

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer

Published:2018-04-01 Issue:4 Volume:4 Page:537
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Petrylak Daniel P.¹,Powles Thomas²,Bellmunt Joaquim³,Braiteh Fadi⁴⁵,Loriot Yohann⁶,Morales-Barrera Rafael⁷,Burris Howard A.⁸,Kim Joseph W.¹,Ding Beiying⁹,Kaiser Constanze⁹,Fassò Marcella⁹,O’Hear Carol⁹,Vogelzang Nicholas J.⁴⁵

Affiliation:

1. Yale Cancer Center, New Haven, Connecticut

2. Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London, United Kingdom

3. Bladder Cancer Center, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, Massachusetts

4. University of Nevada School of Medicine, Las Vegas

5. US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas

6. Gustave Roussy Cancer Campus, University of Paris-Saclay, Villejuif, France

7. Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain

8. Oncology, Sarah Cannon Research Institute, Nashville, Tennessee

9. Genentech, Inc, South San Francisco, California

Publisher

American Medical Association (AMA)